On Tuesday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Mattel, Inc (NASDAQ:MAT), Century Aluminum Co (NASDAQ:CENX), Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), Geron Corporation (NASDAQ:GERN)
Mattel, Inc (NASDAQ:MAT)’s shares dwindled -2.89%, and closed at $23.48, hitting new 52-week low of $23.46. The stock has price to sale ratio of 1.32, however, price to book ratio is 2.70. With recent decline, the year-to-date (YTD) performance reflected a -23.07% decline below last year. During the past month the stocks lose -7.52%, bringing three-month performance to -18.44% and six-month performance to -26.60%. The mean recommendation of analysts for this stock is 2.90. (where 1=Buy, 5=Sale).
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman. The company also provides its products under the Fisher-Price brands, such as Fisher-Price, Little People, BabyGear, Laugh & Learn, Imaginext, Thomas & Friends, Dora the Explorer, Mickey Mouse Clubhouse, Disney Jake, the Never Land Pirates, and Power Wheels.
Century Aluminum Co (NASDAQ:CENX), declined -2.83%, and closed at $13.90. The stock volatility for the week is 5.94%, while for the month remained 6.14%. The company holds consensus target price of $22.63.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 1.15 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 355.60% and Annual EPS growth for the past 5 years is considered as 19.30%.
The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).
Century Aluminum Company, together with its subsidiaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1981 and is headquartered in Chicago, Illinois.
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), dipped -2.83%, and closed at $1.03. The company holds the market capitalization of $746.90M. For the last twelve months, the stock was able to keep return on equity at -64.70%, while return on assets at -35.60%, in response to its return on investment at -25.60%. Its 20-day moving average declined -3.47%, above 50-day moving average of 4.99%, below 200-day moving average of -18.66% from the latest market price of $1.03. The mean recommendation of analysts for this stock is 2.10.(where 1=Buy, 5=Sale).
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs comprise LX4211, an orally-delivered small molecule compound that has accomplished two Phase II clinical trials for the treatment of type 2 diabetes patients, in addition to an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and concluding a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has accomplished two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis.
Geron Corporation (NASDAQ:GERN), dropped -2.83%, and closed at $3.78. The company has the market capitalization of $596.11M. The beta value of the stock is 2.11. On the other hand the stock’s volatility for the week is 5.93%, and for the month is 8.33%. The stock’s price to book ratio is 4.55, however price to sale ratio is 496.72. Analyst’s mean recommendation regarding this stock is 2.50. (where 1=Buy, 5=Sale).
Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
